To facilitate the discovery of small-molecule probes and drugs, ..
Dr. Senanayake’s research interests focus on the development of new asymmetric methods for the synthesis of bioactive molecules and heterocycles and on catalytic, enzymatic, and mechanistic studies. He has published and lectured in the area of practical asymmetric synthesis and many disciplines of organic chemistry how to develop drugs on an economical, greener and practical manner in large-scale operation for rapid development of drugs. He is the co-author >350 papers, patents, book chapters and review articles in many areas of synthetic organic chemistry, drug development and design of improved chemical entities.
The Role of Organic Synthesis in Drug Discovery - …
After the general introduction presented in chapter 1, the following chapters of this thesis focus on the design, synthesis and evaluation of small molecular probes towards the study of proteins and glycans in plant and mammalian cells.
Schreiber is one of four co-founders of the Broad Institute, serving as the Director of the Center for the Science of Therapeutics. Schreiber is a Howard Hughes Medical Institute Investigator, the Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, and has been a member of the National Academy of Sciences since 1995. Schreiber’s research integrates chemical biology and human biology to advance the science of therapeutics. He is known for having developed systematic ways to explore biology, using small molecules and for his role in the development of the field of chemical biology. He discovered principles that underlie information transfer and storage in cells. His work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in an open data-sharing environment. His research has been reported in over 500 publications. Four new anti-cancer drugs that target proteins discovered in the Schreiber laboratory have been approved by the U.S. FDA. A small-molecule dimerizer drug (AP1903) reversed the effects of graft-versus-host disease in acute leukemia patients receiving hematopoietic stem cells engineered to express caspase-9 fused to a drug-responsive, FKBP12-based dimerization domain (NEJM, 2011). Schreiber extended chemical biology principles to medicine by participating in the founding of four biotech companies, each of which has devised novel therapeutic agents that are being tested in human clinical trials or used as FDA-approved drugs: Vertex Pharmaceuticals, ARIAD Pharmaceuticals, ARIAD Gene Therapeutics, and Infinity Pharmaceuticals. More recently, he co-founded Forma Therapeutics and H3 Biomedicines.
Hosted by: Professor Phil Baran & Professor Benjamin Cravatt